Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.

Slides:



Advertisements
Similar presentations
HIV Counseling, Testing and Referral (CTR) Services at Boston Medical Center Vanessa J. Sasso, MSW Manager, HIV CTR Program Center for HIV/AIDS Care and.
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Implementing Rapid HIV Testing: Technologies, Legal and Cost Issues Vanessa Lee, MPH HIV Rapid Testing Coordinator CA Office of AIDS.
Post Marketing Surveillance of Oraquick Rapid HIV Testing Laura Wesolowski, PhD Gale R Burstein, MD, MPH Julia Zhu, MS Steven Ethridge, MT Division of.
Rapid Diagnostic Tests for Syphilis A Preliminary Review of the U. S
Implementing a Laboratory-Based Rapid HIV Testing Algorithm using Two Different Test Kits in a Hospital Emergency Department Jason S. Haukoos 1, MD, MSc,
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics.
Rapid HIV Testing: 2005 Update Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention.
Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
1 Quality System Considerations for Over-The-Counter HIV Testing Devery Howerton, Ph.D. Chief, Laboratory Practice Evaluation and Genomics Branch, Division.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Rapid HIV Tests Norman Moore, Ph.D. Director of Medical Affairs.
Increasing Our Reach through Rapid HIV Testing Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and.
Rapid HIV Testing in an Emergency Department Cook County Bureau of Health Services Chicago, Illinois Centers for Disease Control and Prevention (Cooperative.
Poster Presentation 40th Annual Meeting of IDSA Chicago, Illinois October 26, 2002 Presenting Author: Sabrina Kendrick, MD (312)
Counseling Message: Both rapid tests we ran today were preliminary positive. It is likely that you have HIV. We always want to make absolutely sure, though,
Oral Presentation 2002 National STD Prevention Conference San Diego, California March 6, 2002 Presenting Author: Karen Kroc (312)
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Shelley Facente, Thomas Knoble, Omar Menendez, Teri Dowling San Francisco Department of Public Health, HIV Prevention Section Kevin Delaney Division of.
Implementing Rapid HIV Testing in New York State Mara San Antonio-Gaddy Director Bureau of Direct Program Operations NYSDOH, AIDS Institute.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
HIV Screening and Women’s Health Health Care Education & Training, Inc. Originally developed by: Section 5: Test Options.
Results from the LA rapid testing study: What can they tell us about proposed point of care strategies? Kevin Delaney, MPH Division of HIV/AIDS Prevention.
Rapid HIV Testing: 2003 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.
Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.
Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.
An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test 1 An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test OraSure Technologies, Inc.
*p
1 OraQuick ® ADVANCE ™ HIV 1/2 Antibody Test (Oral Fluid Specimen Type) Blood Products Advisory Committee Meeting March 10, 2006.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,
Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.
ABSTRACT Background: The New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services (NJDHSS, DHAS)) introduced rapid HIV testing.
STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.
In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
Trinity Biotech Fingerstick whole blood sample for HIV OTC test Presented by; Fiona Campbell.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
Rapid HIV Testing In Labor and Delivery Unit Presented by Danielle Joseph-White Public Health Investigator Specialist Houston Department of Health and.
American Society for Microbiology Position on Home Use HIV-1 Testing Patricia Charache, MD Johns Hopkins Medical Institutions Professor of Pathology, Medicine.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
HIV Testing in Medical Settings Mark Thrun, MD Denver Public Health
Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
RAPID HIV TESTING OraQuick ADVANCE HIV 1/2
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
ABSTRACT Purpose: Point-of-care rapid HIV testing is a new way to diagnose HIV disease. The New Jersey Department of Health and Senior Services Division.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
Update Rapid HIV Testing in NJ
California Clinical Laboratory Association
In the Footsteps of the WHO – Rapid HIV Testing in America
Provider Initiated HIV Counseling and Testing
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites
San Francisco Department of Public Health
INTEGRATING HIV AND HCV TESTING.
Quality System Considerations for Over-The-Counter HIV Testing
AIDS in the United States
1985: First HIV-1 ELISA Approved by FDA
A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING
Hepatitis Training in a STD Clinical Program
Presentation transcript:

Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention

Three FDA-approved Rapid HIV Tests Sensitivity (95% C.I.) Specificity (95% C.I.) OraQuick 99.6 (98.5 – 99.9) 100% (99.7 – 100) Reveal 99.8 (99.2 – 100) 99.1 (98.8 – 99.4) Uni-Gold Recombigen 100 (99.5 – 100) 99.7 (99.0 – 100)

Three FDA-approved Rapid HIV Tests Specimen type CLIA category OraQuick Fingerstick, whole blood, (oral fluid?) Waived Reveal Serum, plasmaModerate Complexity Uni-Gold Recombigen Serum, plasma, whole blood Moderate Complexity

OraQuick: Fingerstick, whole blood

Obtain finger stick specimen…

… or whole blood

Loop collects 5 microliters of whole blood

Insert loop into vial and stir

Insert device; test develops in 20 minutes

PositiveNegative Reactive Control Positive HIV-1 Read results in 20 – 40 minutes T T C C

Sold only to “clinical laboratories” To perform CLIA-waived tests, entities must: 1)Enroll in CLIA program 2)Obtain a Certificate of Waiver 3)Pay a biennial fee 4)Follow manufacturers’ instructions 5)Meet state requirements Requirements for OraQuick Testing

Have an adequate quality assurance program Assurance that operators will receive and use instructional materials QA guidelines for OraQuick testing and sample forms: Requirements for OraQuick Testing

Oral fluid specimens: Reduce hazards, facilitate testing in field settings

Reveal HIV-1 Rapid Antibody Test: Serum, Plasma

Centrifuge to obtain serum or plasma

Add 20 drops of buffer to reconstitute conjugate. (Refrigerate to store)

Add 3 drops buffer to moisten membrane

Add one drop of serum or plasma, followed by 3 drops of buffer.

Add 4 drops of conjugate solution

Add 3 drops of buffer to wash

Read results immediately Positive Negative

Uni-Gold Recombigen: Serum, plasma, whole blood

Add 1 drop specimen to well

Add 4 drops of wash solution

Read results in 10 minutes

Point-of-Care Testing To expand testing in non-clinical settings: –Fingerstick or oral fluid specimen –One-step –Easy to interpret –Internal control

The Need for Training Blood & body fluid precautions Obtaining the specimen (finger stick or blood draw) Performing the test Providing test results and counseling Quality assurance OSHA requirements

Remember the tradeoffs… Good News: More HIV-positive people receive their test results. Bad News: Some people will receive a false- positive result before confirmatory testing.

Reports from the 2003 HIV Prevention Conference Promising news with rapid HIV tests for – –Routine screening in medical settings –Increasing receipt of results at CT sites –Screening in labor and delivery –Outreach testing

Routine HIV Screening in Medical Care Settings Cook County Hospital ED, Chicago OraQuick testing since October 02  60% accept HIV testing  98% receive test results  2.8% new HIV positive  80% entered HIV care Now underway in Chicago, Boston, Los Angeles 4 new demonstration projects (Wisconsin, Massachusetts, Los Angeles, New York)

HIV Screening in Acute Care Settings Cook County ED, Chicago2.3% Grady ED, Atlanta2.7% Johns Hopkins ED, Baltimore3.2% HIV testing sites1.3% New HIV+

HIV Screening with OraQuick in Labor and Delivery: the MIRIAD Study Testing of pregnant women in labor for whom no HIV test results are available; 12 hospitals in 5 cities: Atlanta, Chicago, Miami, New Orleans, New York To date  4597 women screened  34 new HIV infections identified  2 false positive OraQuick tests, no false negatives  8 false-positive EIAs

Turnaround Times for Rapid Test Results, Point-of-Care vs Lab Testing Point-of-care testing: median 45 min – (range 30 min – 2.5 hours) Same test in Laboratory: median 3.5 hours – (range 94 min – 16 hours) MMWR 52:36, Sept 16, 2003

OraQuick Outreach to High-risk Persons of Color On-site testing at sites throughout the community Group pretest counseling. Individual testing and post-test counseling. Patrick Keenan MD University of Minnesota Medical School Department of Family Practice and Community Health

OraQuick Fingerstick Results: 7/02 – 6/03 N = 1021 Preliminary positive 5 (0.5%) True positives 4 (0.4%) False Positives 1 (0.1%) Sensitivity4/4 (100%) Specificity1016/1017 (99.9%) Positive Predictive Value4/5 (80%)

Results 99.7% of clients received their test results and post-test counseling. The average time between fingerstick and learning test result was 28 minutes.

Client Survey Results “I would rather have my finger stuck than have blood drawn from my vein” Agree or strongly agree = 95% Disagree or strongly disagree = 5%

Post-Marketing Surveillance 14 states in 2003, expansion in 2004 as more project areas implement rapid testing (Note: Supplement to Program Announcement) Monitoring:  Changes in utilization of testing  Acceptance (choice of tests)  Client and counselor satisfaction  Follow-up on false-positives  Adverse events

Initial Observations 95% of persons opt for the rapid HIV test; 34% of those tested say they would not have been tested if rapid test not available (New York) In one clinic for homeless persons, HIV prevalence among those tested rose from 4% to 12% after introduction of rapid tests (San Francisco) 30% of the number of HIV-positive persons identified in all of last year were identified in the first month rapid testing was introduced (Utah) 98% - 100% of those tested receive their test results

Post-Marketing Surveillance In New York State test sites: 30% increase in persons tested  85% increase in MSM  42% increase in IDU  96% increase in persons with hx of STD diagnosis Counselors’  confidence in their overall role in rapid testing rose from 54% to 100% after first 12 weeks of testing  scores on proficiency specimens at 12 weeks were 100%

Confirmatory Testing For Western blot:  Venipuncture for whole blood  Oral fluid specimen  Dried blood spots on filter paper Confirmatory test essential (not just EIA!)

Additional Resources General and technical information (updated frequently):

Interpreting Rapid Test Results For a laboratory test: Sensitivity : Probability test=positive if patient=positive Specificity : Probability test=negative if patient=negative Predictive value : Probability patient=positive if test=positive Probability patient=negative if test=negative

Example: Test 1,000 persons HIV prevalence = 10% True positive:False positive: Positive predictive value:100/104 = 96% 1004 Test Specificity = 99.6%(4/1000)

Example: Test 1,000 persons Test Specificity = 99.6% (4/1000) HIV prevalence = 10% True positive: 100False positive: 4 Positive predictive value: 100/104 = 96% HIV prevalence = 0.4% True positive:4False positive:4 Positive predictive value:4/8 = 50%

Positive Predictive Value of a Single Test Depends on Specificity & Varies with Prevalence Test Specificity HIV Prevalence Predictive Value, Positive Test 10% 99% 98% 92% 5% 98% 96% 85% 2% 95% 91% 69% 1% 91% 83% 53% 0.5% 83% 71%36% 0.3% 75%60% 25% 0.1% 50% 33% 10% OraQuic k EIAReveal 99.9%99.8%99.1%